Lithotripsy Market Report By Insights, Size, and Growth - 2031

The lithotripsy market is anticipated to expand from US$ 1.4 billion in 2023 to US$ 2.3 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.6% from 2021 to 2031.

The growth of the lithotripsy market is significantly supported by medical reimbursement and coverage for noninvasive lithotripsy procedures. However, the market faces challenges due to an increase in product recalls by the FDA, which can hinder growth. Additionally, the growing preference for lithotripsy techniques in treating coronary lesions is expected to be a prominent trend in the market from 2021 to 2031.

Key Growth Factors:

Introduction of Advanced Lithotripsy Devices

Numerous manufacturers are innovating and developing advanced lithotripsy devices to maintain a competitive edge in the global market. For instance, Boston Scientific has introduced the Lumenis Pulse 120H Holmium Laser System featuring MOSES 2.0 Technology. This technology is adept at treating various stone compositions through techniques such as stone dusting, popcorning, and fragmentation. It enhances energy transmission, leading to more effective lithotripsy treatments compared to traditional holmium pulse devices. In the context of Benign Prostatic Hyperplasia (BPH) treatment, MOSES technology has been shown to reduce treatment duration by enhancing enucleation efficiency and hemostasis compared to standard holmium pulse devices. Similarly, in January 2022, Olympus launched its next-generation SOLTIVE Premium SuperPulsed Laser System, which promises shorter procedure times, improved patient outcomes, and reduced costs compared to conventional Holmium: YAG lithotripsy devices. Thus, the introduction of innovative lithotripsy devices is a significant driver of market growth.

Consequently, the launch of cutting-edge lithotripsy devices is a crucial factor contributing to the expansion of the market.

Report Segmentation and Scope:

• The lithotripsy market is categorized by product type into extracorporeal shock wave lithotripsy devices, intracorporeal lithotripsy devices, and ureteroscopic devices. In 2023, the extracorporeal shock wave lithotripsy devices segment held the largest market share.
   
• By application, the market is divided into segments for kidney stones, ureteral stones, pancreatic stones, bile duct stones, and bladder stones. The kidney stones segment represented the largest share of the market in 2023.
   
• By end user, the market is segmented into hospitals, specialty clinics, and other facilities. The hospitals segment was the leading market segment in 2023.
  
  Insights by Type
  
  The lithotripsy market is divided into extracorporeal shock wave lithotripsy devices, intracorporeal lithotripsy devices, and ureteroscopic devices. The extracorporeal shock wave lithotripsy devices segment dominated the market in 2023. Extracorporeal Shockwave Lithotripsy (ESWL) is a noninvasive method that effectively breaks down stones in the urinary system, pancreas, and bile duct. ESWL is widely recognized as one of the most common techniques for treating kidney stones noninvasively. Moreover, the recurrence rate of renal stones following ESWL treatment is notably low. A clinical study published in the American Journal of Roentgenology indicated that out of 148 patients who underwent ESWL at the University of Florida, only 5% experienced new stone formation post-treatment, significantly lower than the expected recurrence rate of 37-50%.
  
  Regional Overview:
  
  The lithotripsy market report is segmented geographically into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. The report provides a comprehensive analysis of global and regional market trends, key players, regulations, and recent developments.
  
  North America has been the leading market region, with the US holding the largest share in 2023. According to a report from the Korean Urological Association, the prevalence of nephrolithiasis (kidney stones) is notably high in the US. The BD company website states that kidney stones affect approximately 1 in 11 individuals in the US each year, leading to significant healthcare costs and burdens. The average time from diagnosis to treatment is around 18 days, with nearly 50% of patients advised to undergo lithotripsy procedures, predominantly using extracorporeal shockwave lithotripsy (ESWL). Furthermore, lithotripsy is the most frequently recommended noninvasive procedure in the US. According to NewChoiceHealth.com, the average cost of lithotripsy in the US is about US$ 12,800, although prices can vary for outpatient treatments. The following table illustrates the outpatient costs for lithotripsy in Virginia State compared to licensed ambulatory surgical centers recorded in 2018.
  
  Virginia State Hospital Outpatient (US$) Licensed Ambulatory Surgical Center (US$)
  
  Central 8,710 5,385
  
  Eastern 6,273 4,547
  
  Northern 9,796 5,898
  
  Northwestern 9,983 7,133
  
  Southwestern 9,435 NA
  
  Source: Virginia Health Information
  
  Patients undergoing noninvasive lithotripsy procedures in the US can apply for medical reimbursement, which encourages more patients to opt for these procedures. The New York Urology Specialists report indicates that kidney stone treatments are covered by health insurance in the US, which includes coverage for blood tests, consultations with urologists, surgical costs for various noninvasive and surgical procedures (including lithotripsy, ureteroscopy, or percutaneous nephrolithotomy), diagnostic imaging, and more. Consequently, the increasing incidence of kidney stones in the US population is driving the demand for lithotripsy devices, thereby boosting the volume of procedures performed in hospitals and specialized centers due to the benefits of medical reimbursement. Thus, the high prevalence of nephrolithiasis is a key factor propelling the growth of the lithotripsy market.